Emiliano Tamburini
Overview
Explore the profile of Emiliano Tamburini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Milella M, Orsi G, di Marco M, Salvatore L, Procaccio L, Noventa S, et al.
Cancer Med
. 2025 Jan;
14(3):e70364.
PMID: 39861955
Introduction: Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP-ribose) polymerase inhibitors. We analyzed real-world data on the impact of olaparib on survival in metastatic pancreatic...
2.
Avallone A, Giuliani F, De Stefano A, Santabarbara G, Nasti G, Montesarchio V, et al.
J Clin Oncol
. 2024 Nov;
43(7):829-839.
PMID: 39576946
Purpose: To investigate whether intermittent treatment after an induction phase of first-line schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN) prevents or delays the onset of resistance and...
3.
Moretto R, Rossini D, Murgioni S, Ciraci P, Nasca V, Germani M, et al.
JCO Precis Oncol
. 2024 Nov;
8:e2400329.
PMID: 39509668
Purpose: KRASG12D mutation (mut) occurs in about 10%-12% of metastatic colorectal cancer (mCRC). Recently, novel KRASG12D inhibitors have been developed and are currently under investigation in phase I/II clinical trials...
4.
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241289517.
PMID: 39502404
Background: Ascites is common in advanced gastrointestinal cancers with peritoneal metastases (PM) and negatively impacts patient survival. No study to date has specifically evaluated the relationship between ascites, PM and...
5.
Prinzi F, Salani F, Rimini M, Rizzato M, Antonuzzo L, Camera S, et al.
Oncologist
. 2024 Oct;
PMID: 39427227
Background: In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our...
6.
Rimini M, Fornaro L, Rizzato M, Antonuzzo L, Rossari F, Satake T, et al.
Eur J Cancer
. 2024 Jul;
208:114199.
PMID: 39002348
Background: The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy...
7.
Antoniotti C, Rossini D, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, et al.
J Clin Oncol
. 2024 Jun;
42(22):2637-2644.
PMID: 38865678
JCO We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n...
8.
Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, et al.
Target Oncol
. 2024 May;
19(3):359-370.
PMID: 38691295
Background: The TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed cell death ligand 1 (anti-PD-L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary...
9.
Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, et al.
Liver Int
. 2024 Mar;
44(5):1108-1125.
PMID: 38517286
Introduction: Overweight is a negative prognostic factor in the general population in the long term. However, the role of body mass index (BMI) in the short-mid term in advanced tumours...
10.
Fanotto V, Rossini D, Casagrande M, Bergamo F, Spagnoletti A, Santini D, et al.
Cancers (Basel)
. 2023 Nov;
15(22).
PMID: 38001711
Background: The decision to resect or not the primary tumor in asymptomatic patients with synchronous metastatic colorectal cancer (mCRC) is a complex and challenging issue for oncologists, especially when an...